Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer

DISEASE CHARACTERISTICS: * Histologic or cytologic diagnosis of locally advanced or metastatic cancer for which no preferable therapy exists * Measurable or nonmeasurable disease * No CNS metastases or a primary CNS tumor PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * Life expectancy ≥ 12 weeks * WBC count ≥ 3.0 × 10\^9/L * Absolute neutrophil count ≥ 1.5 × 10\^9/L * Platelet count ≥ 100 × 10\^9/L * Hemoglobin ≥ 10 g/dL (6.21 mmol/L) * Bilirubin ≤ 2 times upper limit of normal (ULN) * Alkaline phosphatase ≤ 3 times ULN (5 times ULN if liver metastases are present) * AST and ALT ≤ 3 times ULN (5 times ULN if liver metastases are present) * Serum creatinine \< 1.5 times ULN * No proteinuria at baseline, as demonstrated by either of the following: * Urine protein:creatinine ratio \< 1.0 at screening * Urine dipstick for proteinuria \< 2+ (patients discovered to have ≥ 2+ proteinuria on dipstick urinalysis at baseline must undergo a 24-hour urine collection that demonstrates ≤ 1 g of protein in 24 hours to be eligible for study participation) * No second primary malignancy that could affect compliance with the study or interpretation of the study results * No concurrent serious systemic disorder (e.g., active infection, including HIV) that, in the opinion of the investigator, would compromise the patient's ability to adhere to the study * No known hypersensitivity to bevacizumab or enzastaurin hydrochloride, or to a component of either drug * No prior bevacizumab-related toxicity requiring discontinuation, such as a thromboembolic event, hemorrhage, or serious hypertension * No clinically significant cardiac disease, in the opinion of the investigator, including any of the following: * Myocardial infarction within the past 6 months * Symptomatic angina pectoris * Congestive heart failure not controlled by medications * ECG abnormalities indicative of clinically significant cardiac disease * No evidence of bleeding diathesis or coagulopathy * No nonhealing cutaneous wound or gastrointestinal ulcer * No history of or risk for abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months * No hemoptysis requiring medical attention within the past 3 months * No known history of cerebrovascular accidents or transient ischemic attacks * No clinically significant vascular or peripheral vascular disease * No hypertension not controlled by medical management * No history of hypertensive crisis or hypertensive encephalopathy * No significant traumatic injury within the past 28 days * Able to comply with study or study procedures * Able to swallow tablets * Exhibits compliance and geographic proximity that allow adequate follow-up * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 3 months after completion of study treatment PRIOR CONCURRENT THERAPY: * Recovered from prior therapy * No prior participation in this study or any other study involving enzastaurin hydrochloride * At least 4 weeks since prior chemotherapy (6 weeks for mitomycin C or nitrosoureas) * At least 4 weeks since prior radiotherapy, anticancer hormone therapy, or other investigational therapy * Patients with hormone-refractory prostate cancer receiving luteinizing hormone-releasing hormone analogue therapy (leuprolide or goserelin) prior to study enrollment should continue therapy during study participation * At least 6 weeks since prior bicalutamide * At least 4 weeks since prior flutamide or nilutamide * More than 10 days since prior and no concurrent aspirin \> 325 mg/day * More than 28 days since prior major surgery or open biopsy * More than 7 days since prior core biopsy or other minor surgical procedure, excluding placement of a vascular access device * No concurrent carbamazepine, phenobarbital, or phenytoin * No concurrent systemic anticoagulation * No concurrent chronic use of other nonsteroidal anti-inflammatory drugs * No concurrent routine use of colony-stimulating factors * No concurrent major surgery * No other concurrent chemotherapy, radiotherapy, immunotherapy, or experimental medications * No other concurrent antitumor therapy